WellDoc has entered a commercial partnership agreement with LifeScan Inc., a Johnson & Johnson Diabetes Care Company (JJDCC), to deliver a best-in-class digital health solution for individuals living with Type 2 diabetes.
The combined offering will seek to create a comprehensive, data-driven and payer-reimbursed program for Type 2 diabetes management.
WellDoc’s BlueStar® diabetes management platform and mobile app is the first digital therapeutic approved by the U.S. Food and Drug Administration for adults who live with Type 2 diabetes. As part of the commericial agreement, companies will integrate BlueStar with LifeScan’s OneTouch Verio Flex™ blood glucose monitoring system (with built-in Bluetooth® Smart Technology) and the OneTouch Reveal digital system.
“We’ve made considerable progress in our important relationship with LifeScan, Inc., which began earlier this year via a development agreement and a Johnson & Johnson Innovation – JJDC, Inc. investment in WellDoc. Together, WellDoc and LifeScan will provide those living with Type 2 diabetes a best-in-class diabetes management solution with robust data analytics powered by BlueStar’s patented clinical and behavioral engine,” said Kevin McRaith, CEO of WellDoc. “We will facilitate national adoption of this innovative first-in-class digital health solution. Our goal is to help make a difference in the lives of millions of Americans living with this chronic disease while bringing the U.S. healthcare system cost-savings opportunities.”
